PBMs, the brokers who control drug prices, finally get Washington's attention
For two decades, patients and physicians eagerly awaited a lower-cost version of the world's bestselling drug, Humira, while its maker, AbbVie, fought off potential competitors by building a wall of more than 250 patents ...
May 15, 2023
0
18